Lexeo Therapeutics Inc (LXEO) Stock Price, Quote & News

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 547 9879

Website: www.lexeotx.com

Address:

345 Park Avenue South, 6th Floor, New York, United States

JarvisFlow Oct. 21 at 11:11 AM

HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.

0 · Reply

DonCorleone77 Oct. 17 at 10:56 AM

$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00

0 · Reply

DonCorleone77 Oct. 16 at 8:34 PM

$LXEO Lexeo announces common stock and warrants offering, no amount given

0 · Reply

JarvisFlow Oct. 15 at 2:26 PM

Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.

0 · Reply

Cinoooo Oct. 15 at 12:45 PM

$LXEO okay we got a PT of 30 and hit 8.99 PM blast us thru 9 today and let’s hit double digits.

0 · Reply

Cinoooo Oct. 15 at 1:29 AM

$LXEO one share sold dropped it 2%. Sitting on the sideline watching everything run 20% up got me like

0 · Reply

StreetwiseReports Oct. 10 at 5:05 PM

Therapeutics Company Advances Gene Therapy Breakthrough https://ow.ly/7Vgj50X9Wbc In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. ($LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.

0 · Reply

StreetwiseReports Oct. 9 at 5:24 PM

Biotech Firm Uncovers Breakthrough Gene Therapy in New York https://ow.ly/uQAf50X9kNq Lexeo Therapeutics Inc. ($LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.

0 · Reply

StreetwiseReports Oct. 9 at 5:08 PM

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease https://ow.ly/gYQz50X9kmb Lexeo Therapeutics Inc. ($LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.

0 · Reply

nbkihy8 Oct. 8 at 3:53 PM

$LXEO I have a feeling they push this green today

0 · Reply

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Oct 16, 2025, 11:29 PM EDT - 10 days ago

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Oct 16, 2025, 4:32 PM EDT - 10 days ago

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Oct 7, 2025, 3:22 PM EDT - 19 days ago

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Oct 7, 2025, 12:45 PM EDT - 20 days ago

Lexeo Therapeutics, Inc. - Special Call

Oct 7, 2025, 6:00 AM EDT - 20 days ago

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Aug 14, 2025, 7:30 AM EDT - 2 months ago

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Jun 24, 2025, 7:30 AM EDT - 4 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

May 27, 2025, 7:31 AM EDT - 5 months ago

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 12, 2025, 7:00 AM EDT - 6 months ago

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 5, 2025, 2:19 PM EDT - 6 months ago

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 1, 2025, 9:16 AM EDT - 6 months ago

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Apr 7, 2025, 9:34 AM EDT - 7 months ago

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Apr 7, 2025, 6:00 AM EDT - 7 months ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Mar 24, 2025, 7:00 AM EDT - 7 months ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Jan 7, 2025, 7:30 AM EST - 10 months ago

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 11 months ago

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Nov 13, 2024, 7:30 AM EST - 1 year ago

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 6:14 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 16, 2024, 1:17 PM EDT - 1 year ago

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

May 9, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Apr 9, 2024, 5:26 PM EDT - 1 year ago

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Mar 13, 2024, 4:22 PM EDT - 1 year ago

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Mar 11, 2024, 7:42 AM EDT - 1 year ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Feb 5, 2024, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Dec 18, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Dec 11, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 4, 2023, 12:21 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

ATGL BLMZ HG IPO IPOS KVUE NCI

Nov 3, 2023, 12:39 PM EDT - 2 years ago

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Oct 31, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 2, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

JarvisFlow Oct. 21 at 11:11 AM

HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.

0 · Reply

DonCorleone77 Oct. 17 at 10:56 AM

$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00

0 · Reply

DonCorleone77 Oct. 16 at 8:34 PM

$LXEO Lexeo announces common stock and warrants offering, no amount given

0 · Reply

JarvisFlow Oct. 15 at 2:26 PM

Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.

0 · Reply

Cinoooo Oct. 15 at 12:45 PM

$LXEO okay we got a PT of 30 and hit 8.99 PM blast us thru 9 today and let’s hit double digits.

0 · Reply

Cinoooo Oct. 15 at 1:29 AM

$LXEO one share sold dropped it 2%. Sitting on the sideline watching everything run 20% up got me like

0 · Reply

StreetwiseReports Oct. 10 at 5:05 PM

0 · Reply

StreetwiseReports Oct. 9 at 5:24 PM

0 · Reply

StreetwiseReports Oct. 9 at 5:08 PM

0 · Reply

nbkihy8 Oct. 8 at 3:53 PM

$LXEO I have a feeling they push this green today

0 · Reply

ZenfireTrading Oct. 8 at 1:33 PM

$LXEO Sometimes you only take what you can get! And this is a prime example of it. If you want to see the long/short quant side of the market, visit zenfiretrading.com/join ⚡✨

0 · Reply

boncuk Oct. 8 at 12:38 PM

$BJDX $PCSA $TMQ $LXEO thank u for alerts ...

0 · Reply

JarvisFlow Oct. 8 at 9:31 AM

HC Wainwright & Co. has updated their rating for Lexeo Therapeutics ( $LXEO ) to Buy with a price target of 15.

0 · Reply

StocktwitsNews Oct. 8 at 4:11 AM

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In $LXEO https://stocktwits.com/news/equity/markets/lexeo-therapeutics-stock-hits-11-month-high-on-bullish-analyst-calls-for-friedreich-s-ataxia-gene-therapy/ch6E3ylR3L3

0 · Reply

Prosperity_Trades Oct. 7 at 11:55 PM

$TMQ Play of the day with $CISS $GLTO $LXEO

1 · Reply

DayTrade_4Life Oct. 7 at 9:37 PM

Today's results from the Watchlist and Alerts. See profile for more info and join us. GLTO: $12 to 36.25 (202%) Alert BQ: $22.05 to 46.70 (111%) Weekly Watchlist PRHI: 1.40 to 2.83 (102%); $2 breakout (41%) WL SPRB: $225 to $383 (70%) WL BURU: .30 to .49 (63%) Alert $BJDX: 1.76 to 3.06 (73%); $2 breakout (53%) WL $PCSA: .35 to .44 (25%) WL $TMQ: 5.50 to 7.98 (45%); 7.05 breakout (13%) WL $LXEO: $9 to $10.02 (11%) Alert

1 · Reply

GuyFawkes_EOD Oct. 7 at 8:37 PM

$LXEO They sure got the SP pinned 🤔

0 · Reply

RunnerSignals Oct. 7 at 8:35 PM

Top Gainers: $TMQ $LXEO $BURU Top Losers: $AEHR $HUMA Full Story here... https://stocksrunner.com/news/2025-10-07-top-movers-and-shakers-shake-markets

0 · Reply

Hernandrod12 Oct. 7 at 8:24 PM

$LXEO $BURU

0 · Reply

nevermind889 Oct. 7 at 8:03 PM

$APLT Solid finish and nice AH. Great volume! Day #3 above 1$. Hoping to follow in $DVLT footstep and hit 2.5$ very soon! $LXEO $RVPH

0 · Reply

anachartanalyst Oct. 7 at 7:03 PM

$LXEO https://anachart.com/wp-content/uploads/ana_temp/1759863767_soc-img.jpg

0 · Reply

JarvisFlow Oct. 7 at 5:56 PM

Chardan Capital has updated their rating for Lexeo Therapeutics ( $LXEO ) to Buy with a price target of 17.

0 · Reply

Market Cap	498.43M
Revenue (ttm)	0.00
Net Income (ttm)	-98.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,077,901
Avg Vol	949,694
Day's Range	N/A - N/A
Shares Out	54.00M
Stochastic %K	62%
Beta	1.66
Analysts	Strong Sell
Price Target	$19.22